On April 13, 2026 AstraZeneca reported the company has secured marketing approval from China’s National Medical Products Administration (NMPA) for Imjudo (tremelimumab). The CTLA-4 inhibitor is approved for use in combination with Imfinzi (durvalumab) and platinum-based chemotherapy as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are negative for EGFR sensitive mutations and ALK alterations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Regulatory Approval & Clinical Basis
Component Detail
Regimen Imjudo (tremelimumab) + Imfinzi (durvalumab) + Platinum Chemotherapy
Indication 1L metastatic NSCLC (EGFR-/ALK-)
Basis for Approval Phase III POSEIDON clinical trial
Dosing Schedule Tremelimumab: 5 cycles; Durvalumab + Chemo: 4 cycles

POSEIDON Trial Key Results
Endpoint Combination Regimen Chemotherapy Alone Hazard Ratio (HR) p-value
Overall Survival (OS) Median 14.0 months; 2-year rate ~33% Median 11.7 months; 2-year rate 22% HR 0.77 (95% CI: 0.65–0.92) 0.00304
Progression-Free Survival (PFS) Significant improvement — HR 0.72 (95% CI: 0.60–0.86) 0.00031
Safety Consistent with known profiles of Imjudo and Imfinzi; no new safety signals identified

Drug Mechanism & Strategic Context
Mechanism of Action: Tremelimumab, a first-generation anti-CTLA-4 monoclonal antibody (originally from Pfizer), blocks the CTLA-4 checkpoint on T-cells, thereby enhancing their activation and anti-tumor immune response.
Differentiated IO Approach: This approval establishes AstraZeneca’s unique STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) in China, differentiating it from other PD-(L)1-based combinations by adding a short course of CTLA-4 inhibition for a potent, yet time-limited, immune boost.
Addressing High Unmet Need: The approval provides a new, more effective standard of care for the large population of Chinese NSCLC patients without actionable EGFR or ALK drivers, who have historically relied on chemotherapy alone.
Market Impact
Competitive Edge: The significant 23% reduction in risk of death and improved long-term survival rates position the Imjudo/Imfinzi combo as a highly compelling option in the crowded first-line NSCLC market.
Franchise Expansion: This approval significantly broadens the commercial footprint of AstraZeneca’s immuno-oncology franchise in China, leveraging the established presence of Imfinzi.
Global Validation: The NMPA’s decision, based on the global POSEIDON data, reinforces the regimen’s efficacy and safety, supporting its adoption as a new global standard of care.

(Press release, AstraZeneca, APR 13, 2026, View Source [SID1234665020])